ArticleBrain and behavior2026
Psychedelics in Mental Health: Opportunities and Challenges.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Psychedelic and substance-assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. However, as the field moves from early efficacy trials toward clinical implementation, major questions remain regarding therapeutic mechanisms, psychological support models, safety, ethics, accessibility, and the role of subjective experience. This editorial introduces the Brain and Behavior special issue "Psychedelics in Mental Health: Opportunities and Challenges," which brings together empirical studies, reviews, clinical perspectives, a case report, and commentaries addressing these emerging priorities. Across the special issue, a central theme is that psychedelic therapy cannot be understood as a pharmacological intervention alone. Contributions highlight the importance of therapeutic relationships, preparation, integration, music, touch, external therapist involvement, peer support, cultural context, and patient expectations in shaping outcomes. Several manuscripts examine the phenomenology of psychedelic and ketamine experiences, emphasizing that subjective meaning-making, expectancy, and altered states are not incidental features but potentially central aspects of therapeutic change and clinical risk. Other articles consider implementation challenges, including models of care for veterans, the perspectives of peer support workers, global mental health equity, and culturally responsive access. Mechanistic and translational work further broadens the field by examining neuroplasticity, rapid-acting interventions for suicidality, and developmental perspectives on psychedelic use. Collectively, the articles in this special issue illustrate a field at an important inflection point. Psychedelic research requires greater conceptual precision, careful attention to safety and consent, and implementation frameworks that prioritize equity and cultural appropriateness. The promise of psychedelics in mental health lies not only in their potential for rapid symptom reduction, but also in their capacity to challenge and expand prevailing models of therapeutic change, integrating biological, psychological, relational, cultural, and systems-level perspectives on healing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.